A major breakthrough in treating spinal muscular atrophy (SMA) now offers meaningful improvement for a wider range of children living with this devastating condition. SMA is a genetic disorder that erodes the motor neurons responsible for muscle movement, leaving many young children unable to sit, crawl, or walk and eventually threatening their ability to breathe.
Until recently, gene therapy for SMA was approved only for babies under the age of two. Delivered through the bloodstream, that one-time treatment could halt disease progression if given very early, before too much nerve damage occurred.
Older children, teens, and adults with more advanced symptoms were largely excluded because the disease had already caused significant damage by the time they were diagnosed and because higher systemic doses raised safety concerns.
Now, scientists and clinicians have demonstrated dramatic improvements using a modified version of the therapy for patients aged two to 18. This new approach delivers the corrective gene directly into the spinal fluid, allowing a fixed, one-time dose to be safely administered without depending on body weight. In clinical trials, children who could not previously sit up or climb stairs gained new motor abilities over the course of a year following treatment.
Based on these results, the FDA has approved this intrathecal gene therapy for patients aged two and older, making it the first gene replacement option available across a broader age range of SMA sufferers. This milestone not only expands treatment to many who previously had limited options, but also signals growing momentum in the field of genetic medicine for tackling neurological and muscular disorders once considered untreatable.
As researchers continue to refine and expand gene therapies, this success story brings renewed hope to families and highlights how advances in biotechnology are transforming the future of rare disease care.